REPLICor Inc. To Participate At The 6th DIA / FDA Oligonucleotide-Based Therapeutics Conference

NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will be an invited participant at the 6th DIA / FDA Oligonucleotide-Based Therapeutics Conference to be held September 9-11, 2015 in Washington. This conference is jointly convened by the DIA (Develop Innovate Advance) organization and the US Food and Drug Administration to showcase and educate on advances, safety and challenges in the field of oligonucleotide-based therapeutics.

Help employers find you! Check out all the jobs and post your resume.